Given that restoring cholesterol homeostasis is associated with neuroprotection and that new tools for the modulation and in vivo imaging of CYP46A1 activity are being developed, our data suggest that CYP46A1 could represent a treatment target or its activity a biomarker of underlying pathological processes that contribute to MS progression. Here, CYP46A1 is linked to myeloid sarcoma.